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PocketBackground & aims: Genetic factors in class II human leukocyte antigen (HLA) have been reported to be
associated with inter-individual variation in hepatitis B virus (HBV) vaccine response. However, the
mechanism underlying the associations remains elusive. In particular, the broad linkage disequilibrium
in HLA region complicates the localization of the independent effects of genetic variants. Thus, the pre-
sent study aimed to identify the most probable causal variations in class II HLA loci involved in the
immune response to HBV vaccine.
Methods: We performed a case-control study to assess whether HLA-DRB1, -DQB1, and -DPB1 4-digit alle-
les were associated with the response to primary HBV vaccination in 574 healthy Japanese students. To
identify causative variants, we next assessed independently associated amino acid variants in these loci
using conditional logistic regression analysis. Furthermore, to clarify the functional effects of these vari-
ants on HLA proteins, we performed computational structural studies.
Results: HLA-DRB1⁄01:01, HLA-DRB1⁄08:03, HLA-DQB1⁄05:01, and HLA-DPB1⁄04:02 were significantly
associated with sufficient response, whereas HLA-DPB1⁄05:01 was associated with poor response. We
then identified amino acids independently associated with sufficient response, namely, leucine at posi-
tion 26 of HLA-DRb1 and glycine-glycine-proline-methionine at positions 84–87 of HLA-DPb1. These
amino acids were located in antigen-binding pocket 4 of HLA-DR and pocket 1 of HLA-DP, respectively,
which are important structures for selective binding of antigenic peptides. In addition, the detected vari-
ations in HLA-DP protein were responsible for the differences in the electrostatic potentials of the pocket,
which can explain in part the sufficient/poor vaccine responses.
Conclusion: HLA-DRb1 position 26 and HLA-DPb1 positions 84–87 are independently associated with
anti-HBs production against HBV vaccine. Our results suggest that HBsAg presentation through these
HLA pocket structures plays an important role in the inter-individual variability of HBV vaccination.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction people, approximately 30% of the global population, show serolog-Hepatitis B virus (HBV) is a major global health issue due to its
high prevalence and related mortality. It is estimated that 2 billionical evidence of current or past HBV infection, and 240 million peo-
ple worldwide are chronically infected with HBV [1–4].
HBV vaccination is the mainstay of HBV prevention. However,
vaccine failure occurs in 5–10% of recipients: individuals who can-
not produce a protective level of antibodies against the hepatitis B
surface antigen (anti-HBs) after a standard vaccine course [5].
Although the mechanisms that determine the different vaccine
responses are not fully understood, the complex interplay between
hepatitis B surface antigen (HBsAg) and host factors influences the
different immune response among individuals.
704 A. Sakai et al. / Vaccine 35 (2017) 703–710The heritability of the response to HBV vaccination has been
reported to be 77% [6]. Human leukocyte antigen (HLA) loci have
been reported as host genetic factors for the HBV vaccine response
[7–12]. The function of HLA is to present antigenic peptides to CD4
+ or CD8+ T lymphocytes and to initiate subsequent immune
responses. Recently, two genome-wide association studies
(GWASs) have demonstrated strong associations of single nucleo-
tide polymorphisms (SNPs) in the regions of HLA-DR and -DP with
the HBV vaccine response [13,14]. Thus, we hypothesize that class
II HLA is the leading candidate for genetic determinants of HBV
vaccine response [15,16]. However, the mechanism of class II
HLA molecules in the immune response to HBV vaccination is
not completely understood. In addition, extensive linkage disequi-
librium (LD) in HLA regions [17] complicates the localization of the
independent effects of each variant [18,19].
Therefore, in the present study, we aimed to address whether
independently contributing amino acid variants exist in class II
HLA proteins and also to determine the potential molecular mech-
anisms underlying the associations. One possible hypothesis is that
the vaccine response is regulated by specific amino acids located at
key HLA structures, i.e. antigen-binding sites, which may alter the
immune response to HBsAg. To this end, we elucidated the associ-
ations between HLA-DRB1, -DQB1, and -DPB1 alleles and the
response to primary HBV vaccination. Based on the genotyping
data, we searched for independently associated amino acid vari-
ants in the antigen-binding site of class II HLA using conditional
logistic regression analysis and explored the effects of these vari-
ants on the protein structure.2. Participants and methods
2.1. Participants
Participants were recruited from healthy students studying at
the University of Tsukuba and Iwate Medical University, Japan.
All participants received their first HBV vaccine during this study.
Students who were seropositive for HBsAg and/or antibodies
against hepatitis B core antigen, or who had anti-HBs prior to
enrollment were excluded. In total, 578 students were enrolled
from June 2013 to August of 2014, and statistical analysis was per-
formed for 574 participants whose HLA-DRB1, HLA-DQB1, and HLA-
DPB1 alleles were successfully genotyped. The characteristics of
the participants are described in Table 1.2.2. Vaccination and serological testing
All participants received a subcutaneous dose of 10 lg of
recombinant HBV vaccine (Bimmugen, Kaketsuken, Kumamoto,
Japan) three times: the initial dose and then at 1 and 6–12 months
after the initial dose. The serum anti-HBs titer was measured atTable 1
Characteristics of participants.
Case (
Non-responder
<10 mIU/mL
Number of participants 27 (4.7%)
Age at first dose (years)
Mean (range) 23.4 (19–33)
Gender
Male 19
Female 8
GMT (mIU/mL) 4.7
GMT: geometrical mean titer of anti-hepatitis B surface antigen antibody.30–60 days after the final dose using a chemiluminescent
immunoassay (Architect, Abbott Japan Co., Ltd., Tokyo, Japan).
We classified the participants according to their anti-HBs titers:
less than 10 mIU/mL (non-responders), 10–100 mIU/mL (low-
responders), andP100 mIU/mL (responders). For statistical analy-
sis, participants with poor responses, i.e., non-responders and low-
responders, were categorized as ‘‘cases”, and those with sufficient
responses, i.e., responders were categorized as ‘‘controls”.
2.3. Genotyping
DNAwas extracted fromwhole blood and purified using a Quick
Gene DNA whole blood kit (Kurabo Industries Ltd., Osaka, Japan).
Four-digit HLA-DRB1, HLA-DQB1, and HLA-DPB1 alleles were geno-
typed based on exon 2 of each locus using the polymerase chain
reaction (PCR)-sequence-specific oligonucleotide probe method
with WAK Flow genotyping kits (Wakunaga, Hiroshima, Japan).
2.4. Evaluation of linkage disequilibrium between the detected alleles
Haplotype frequencies were calculated using Arlequin v3.5 soft-
ware [20]. To evaluate the LD between each detected allele, the
commonly used LD indices D0 and r2 were calculated from the fre-
quencies of the related alleles and haplotypes.
2.5. Amino acid analysis
The amino acid polymorphisms of exon 2 of all alleles in three
class II HLA loci were obtained from the IPD-IMGT/HLA Database
release 3.20.0 (April 2015; https://www.ebi.ac.uk/ipd/imgt/hla/)
corresponding to 4-digit alleles of each locus. There were a total
of 271 amino acid positions, including 32 polymorphic positions
from 91 positions in HLA-DRb1, 30 polymorphic positions from
91 positions in HLA-DQb1, and 22 polymorphic positions from 89
positions in HLA-DPb1. To assess the responsible amino acids, we
first examined the amino acid positions that showed independent
associations with the hepatitis B vaccine response using a logistic
regression model, as previously described [17]. Next, we evaluated
the contribution of the prevalence of each amino acid variant at the
detected positions using Fisher’s exact test.
2.6. Structural studies of HLA-DR and -DP molecules
To compare the differences between responder-associated and
poor responder-associated HLA protein structures, the detected
amino acid positions in three-dimensional structures and the elec-
trostatic potentials were assessed using the Molecular Operating
Environment program (MOE; Chemical Computing Group; http://
www.chemcomp.com/). The protein structural data were obtained
from Protein Data Bank Japan (PDBj: http://pdbj.org/) entries, as
follows: 1AQD, 3WEX, and 3LQZ for HLA-DR1 (HLA-DRB1⁄01:01),n = 156) Control (n = 418)
Low-responder Responder
10 to <100 mIU/mL 100 6mIU/mL
129 (22.5%) 418 (72.8%)
22.4 (19–39) 20.6 (19–33)
82 166
47 252
42.7 746.1
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DPB1⁄02:01), respectively. Although protein structural data were
not available for the responder-associated HLA-DP4, the targeted
amino acid residues, such as residues 84–87 of HLA-DPb1 in
3LQZ, were exactly the same as those of HLA-DPB1⁄04:01 and -
DPB1⁄04:02. Therefore, we used 3LQZ to compare the effects of
the detected amino acid variants. Using these data, protonation
and minimization were performed, and the Poisson-Boltzmann
electrostatic potentials of the HLA-DR and -DP protein surfaces
were calculated.
2.7. Statistical analysis
Associations between HLA-DRB1, -DQB1, -DPB1 alleles, and the
response to HBV vaccination were assessed using Fisher’s exact
test from two-by-two allele frequency tables. Factors having a P
lower than the threshold with Bonferroni correction were consid-
ered statistically significant; the thresholds were set at
a = 0.05/60 (8.33  104) for HLA-DRB1, HLA-DQB1, and HLA-DPB1
alleles, and a = 0.05/271 (1.85  104) for amino acids on the basis
of the number of detected alleles and amino acid positions. Alleles
showing significant associations with ‘‘cases” (with an odds ratio
[OR] > 1.0) were defined as ‘‘risk alleles”, whereas those showing
significant associations with controls (with an OR < 1.0) were
defined as ‘‘protective alleles”. For statistical analyses, R ver3.1.1
(https://www.r-project.org/) and SPSS software version 22.0 (IBM
Corp. Armonk, NY) were used.
2.8. Ethical statement
All participants were recruited after they had provided written
informed consent. The study protocol was in accordance with the
Declaration of Helsinki and the Ethical Guidelines for HumanTable 2
Association of HLA-DRB1, -DQB1, and -DPB1 alleles with the respon
Allele Frequency
(%)
Case
Count (%) C
(2n = 1,148) (2n = 312) (
DRB1
DRB1*01:01 5.2 4 (1.3)
DRB1*04:06 3.6 17 (5.4)
DRB1*08:03 7.2 9 (2.9)
DRB1*09:01 14.5 56 (17.9) 1
DRB1*12:01 3.4 5 (1.6)
DRB1*14:06 1.8 10 (3.2)
DQB1
DQB1*05:01 5.7 4 (1.3)
DQB1*06:04 5.5 9 (2.9)
DPB1
DPB1*04:01 4.3 5 (1.6)
DPB1*04:02 9.9 14 (4.5) 1
DPB1*05:01 39.4 157 (50.3) 2
Fisher’s exact P values and ORs were calculated using the allelic m
Alleles with P < 0.05 are listed. (See Supplementary Tables S1–S3
Shaded columns indicate P < a (a = 0.05/60).Genome/Gene Analysis Research of the Ministry of Health, Labor,
and Welfare of Japan and was approved by the Research Ethics Com-
mittees of the University of Tsukuba and Iwate Medical University.3. Results
3.1. Associations between HLA-DRB1, -DQB1, and -DPB1 alleles and
the response to primary HBV vaccination
In the present study, 4.7% (27/574) of the participants were
non-responders (anti-HBs <10 mIU/mL), 22.5% (129/574) were
low-responders (10–100 mIU/mL), and 72.8% (418/574) were
responders (P100 mIU/mL; Table 1). The number of men was sig-
nificantly higher than the number of women in the case group
(P < 0.0001, OR = 2.79, 95% confidence interval [CI] = 1.90–4.09).
In total, 31 HLA-DRB1, 14 HLA-DQB1, and 15 HLA-DPB1 alleles were
identified. The frequencies of the identified alleles at each locus
were concordant with the frequencies determined by the HLA Lab-
oratory (Kyoto, Japan) for the Japanese population [21] and with
those determined for healthy Japanese controls in previous reports
(Supplementary Table S1 for HLA-DRB1 [22], Supplementary
Table 2 for HLA-DQB1 [23], and Supplementary Table 3 for HLA-
DPB1 [24,25]).
In our case-control study, we assessed the association between
HLA alleles with anti-HBs production by HBV vaccination and
revealed 11 alleles with P < 0.05 (listed in Table 2). Among them,
1 risk allele in HLA-DPB1, 2 protective alleles in HLA-DRB1, and 1
protective allele in HLA-DQB1 and -DPB1 reached statistical signif-
icance after considering multiple testing. HLA-DPB1⁄05:01 was the
most prevalent allele, identified in 39.4% of the participants, and
was significantly associated with a poor response to the primary
HBV vaccination (P < 0.0001, OR = 1.86, 95% CI = 1.43–2.42),
whereas HLA-DRB1⁄01:01, HLA-DRB1⁄08:03, HLA-DQB1⁄05:01, andse to primary HBV vaccination.
Control 
ount (%) P value OR (95% CI)
2n = 836)
56 (6.7) 0.0001 0.18 (0.07–0.50)
24 (2.9) 0.0478 1.95 (1.03–3.68)
74 (8.9) 0.0003 0.31 (0.15–0.62)
10 (13.2) 0.0473 1.44 (1.02–2.05)
34 (4.1) 0.0434 0.38 (0.15–0.99)
11 (1.3) 0.0456 2.48 (1.04–5.91)
61 (7.3) <0.0001 0.16 (0.06–0.46)
54 (6.5) 0.0190 0.43 (0.21–0.88)
44 (5.3) 0.0049 0.29 (0.12–0.75)
00 (12.0) 0.0001 0.35 (0.19–0.61)
95 (35.3) <0.0001 1.86 (1.43–2.42)
odel.
for all examined alleles).
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response (P = 0.0001, OR = 0.18, 95% CI = 0.07–0.50; P = 0.0003,
OR = 0.31, 95% CI = 0.15–0.62, P < 0.0001, OR = 0.16, 95% CI = 0.06–
0.46; P = 0.0001, OR = 0.35, 95% CI = 0.19–0.61; respectively; Table 2).
The LD of the detected alleles is shown in Supplementary
Table 4. Strong LD was observed between HLA-DRB1⁄01:01 and
HLA-DQB1⁄05:01 (D0 = 1.00, r2 = 0.92). The DRB1⁄08:03-DQB1⁄05:01
haplotype was not observed in our dataset, indicating that associ-
ations of these alleles were not explained by the linkage. The D’ of
the other detected alleles varied from 0.17 to 0.79.
3.2. Amino acid variants associated with the HBV vaccine response
Next, we examined all the amino acid variants in exon 2 of HLA-
DRB1, -DQB1, and -DPB1 loci. Four polymorphic amino acidFig. 1. Amino acid variants associated with the HBV vaccine response. The associated am
small open circles represent log10 (P values) for the tested amino acid positions. The h
 104. (A) Amino acid position 26 of HLA-DRb1 showed the strongest association with th
by exon 2 of HLA-DRB1, -DQB1, and -DPB1. (B) Controlling for position 26 of HLA-DRb
controlling for position 26 of HLA-DRb1 and position 84 of HLA-DPb1, no significant
Supplementary Table 5.positions in HLA-DRb1 (positions 11, 16, 26, and 30), one position
in HLA-DQb1 (position 57), and six positions in HLA-DPb1 (posi-
tions 35, 55, and 84–87) showed significant associations
(Pomnibus < 1.85  104) with the response to primary HBV vaccina-
tion. To detect the independent contribution of the variants while
considering the effects of the strong LD, we then used a conditional
logistic regression analysis, as previously described [17]. The most
significant amino acid position in three major class II HLA loci was
position 26 of HLA-DRb1 (Pomnibus = 2.61  107). After controlling
for position 26 of HLA-DRb1, the significance of positions 11, 16, 30
in HLA-DRb1; 57 in HLA-DQb1; 35 in HLA-DPb1 disappeared, but
positions 55 and 84–87 of HLA-DPb1 remained significant and
positions 84–87 of HLA-DPb1 had the lowest P value
(Pomnibus = 2.97  105), indicating their independent associations.
These four sequential amino acids (positions 84–87) in HLA-DPb1ino acid positions were identified using conditional logistic regression analysis. The
orizontal dashed black lines indicate the significance threshold of Pomnibus = 1.85 -
e HBV vaccine response among all of the polymorphic amino acid positions encoded
1 revealed an independent association for positions 84–87 of HLA-DPb1. (C) After
ly associated position was observed. Detailed association results are available in
Table 3
Amino acid residues associated with the HBV vaccine response.
Amino 
acid 
positions
Amino 
acid 
residues
Frequency P value OR 95% CI Explainable 
4-digit allelesCase
(2n = 312)
(%)
Control
(2n = 836)
(%)
position
26 of
DR 1
Y 57 (18.3) 112 (13.4) 0.0399 1.44 1.02–2.05 DRB1*09:01
F 244 (78.2) 609 (72.8) 0.686 1.34 0.98–1.82 DRB1*04:06
DRB1*14:06
L 11 (3.5) 115 (13.8) <0.0001 0.23 0.12–0.43 DRB1*01:01
DRB1*12:01
positions 
84–87 of 
DP 1
GGPM 88 (28.2) 365 (43.7) <0.0001 0.51 0.38–0.67 DPB1*04:01
DPB1*04:02
DEAV 224 (71.8) 471 (56.3) <0.0001 1.97 1.49–2.62 DPB1*05:01
Fisher’s exact P values and ORs were calculated for the presence versus absence of each amino acid variant. P values statistically
significant after correction of the significance level (a = 0.05/271) are indicated as shaded columns.
Y: Tyrosine, F: Phenylalanine, L: leucine, GGPM: glycine-glycine-proline-methionine, DEAV: aspartic acid-glutamic acid-alanine-
valine.
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reported previously [26]. After controlling for both position 26 of
HLA-DRb1 and position 84 of HLA-DPb1, the significance of posi-
tion 55 in HLA-DPb1 disappeared and no significant association
was observed. (Fig. 1 and Supplementary Table 5).
Assessment of all the variants at independently associated
amino acid positions clarified that leucine at position 26 (Leu26)
of HLA-DRb1 and glycine-glycine-proline-methionine (GGPM) at
positions 84–87 of HLA-DPb1 were significantly associated with
the sufficient vaccine response (responder-associated amino acids;
P < 0.0001, OR = 0.23, 95% CI = 0.12–0.43; P < 0.0001, OR = 0.51,
95% CI = 0.38–0.67, respectively), whereas the sequence of aspartic
acid-glutamic acid-alanine-valine (DEAV) at positions 84–87 of
HLA-DPb1 was significantly more frequent in poor responders
(P < 0.0001, OR = 1.97, 95% CI = 1.49–2.62; Table 3). Notably, theFig. 2. Structural studies of the HLA-DR1 molecule. (A) A three-dimensional ribbon mo
shown. HLA-DRa1 (4Glu-96Pro) is colored silver, and HLA-DRb1 (4Arg-96Glu) is colored p
and the other associated variants (b11,16,30) are indicated by a pink ball-stick model. (B) T
red, those greater than 80 kcal/mol blue, and neutral potentials are colored white. The yell
The green area shows the surface close to Leu26 (within 4.5 Å) in (B).detected amino acid variants completely explained the associa-
tions of the above-mentioned HLA-DP alleles; the poor
responder-associated amino acids (i.e., DEAV) at positions 84–87
of HLA-DPb1 tagged the risk allele such as HLA-DPB1⁄05:01,
whereas the responder-associated amino acids (i.e., GGPM) at the
same position were commonly found in the protective alleles, such
as HLA-DPB1⁄04:02 and -DPB1⁄04:01.
3.3. Structural studies of the HLA-DR and -DP molecules
Amino acid variations in class II HLA proteins are the basis for
differential binding of antigenic peptides. In particular, the poly-
morphic ‘‘pockets” of the antigen-binding groove in class II HLA
proteins play a critical role in peptide selection [27]. To explore
the effects of the detected amino acid residues on the HLA proteindel of the HLA-DR1 (PDB:1AQD) molecule carrying responder-associated Leu26 is
ink. The variant with the lowest P value (Leu26) in the b chain is indicated in green,
he electrostatic potential of HLA-DR1. Potentials less than 80 kcal/mol are colored
ow arrow indicates Leu26 of DRb1, which is in pocket 4 of the HLA-DR molecule. (C)
Fig. 3. Structural studies of the HLA-DP molecules. The ribbon model and the electrostatic properties of HLA-DP molecules carrying responder-associated/poor responder-
associated amino acid residues are compared in A and B. The variants with the lowest P values (b84–87) are indicated in green, and the other associated variant (b55) is
indicated by the pink ball-stick model. Potentials less than 80 kcal/mol are colored red, those greater than 80 kcal/mol are colored blue, and neutral potentials are colored
white. (A) HLA-DP2 (PDB:3LQZ) molecule carrying the responder-associated amino acid variants (Gly-Gly-Pro-Met) at positions 84–87. HLA-DPa1 (1Ile-119Val) is colored
silver, and HLA-DPb1 (3Ser-96Arg) is colored cyan. The bottom of pocket 1 consists of 84Gly (yellow arrow), whereas pocket 9 consists of 55Asp (orange arrow). (B) HLA-DP5
(PDB:3WEX) molecule carrying the poor responder-associated amino acid variants (Asp-Glu-Ala-Val) at positions 84–87. HLA-DPa1 (1Ile-115Pro) is colored silver, and HLA-
DPb1 (4Pro-95Pro) is colored cyan. The bottom of pocket 1 consists of 84Asp (yellow arrow), whereas pocket 9 consists of 55Glu (orange arrow).
708 A. Sakai et al. / Vaccine 35 (2017) 703–710structure, we performed computational structural studies. The
genetically significant amino acid positions in the crystal structure
of the representative HLA-DR and HLA-DP molecules are shown in
Figs. 2 and 3. Importantly, residue 26 of HLA-DRb1 was located at
the bottom of the pocket 4 (Fig. 2C), which interacted directly with
the antigen peptides and contributed substantially to the selective
recognition of the immunogenic epitope [28]. Additionally, Leu26
was found to be hydrophobic (Fig. 2B).
Residue 84 of HLA-DPb1 chain also constituted the bottom of
pocket 1 of HLA-DP molecules (Fig. 3). In our cohort, all partici-
pants had either the GGPM or DEAV motif at positions 84–87,
and the electrostatic properties differed between the two motifs;
the responder-associated amino acid variants (i.e., GGPM) caused
pocket 1 to become hydrophobic (Fig. 3A), whereas the poor
responder-associated amino acid variants (i.e., DEAV), particularly
aspartic acid at position 84, induced a negative charge at the sur-
face of the pocket (Fig. 3B), implying that these differences would
affect the antigen-binding affinity of the protein.
Meanwhile, it was difficult to determine whether the associated
residues 11 and 30 of HLA-DRb1 and residue 55 of HLA-DPb1,
which formed pocket 6 of HLA-DR and pocket 9 of HLA-DP, also
influenced the properties of the antigen-binding pockets, or
whether their associations only resulted from the strong LD of
the top two positions mentioned above.
4. Discussion
In the present study, we conducted 4-digit genotyping of HLA-
DRB1, HLA-DQB1, and HLA-DPB1 loci in Japanese students receivinga primary HBV vaccination and performed an association study
evaluating the humoral immune response to HBsAg. Our key find-
ings are as follows; (1) significantly associated protective alleles
were found at all loci of HLA-DRB1, HLA-DQB1, and HLA-DPB1; (2)
There were independently associated amino acid variants in HLA-
DRb1 and -DPb1; (3) these amino acids were located on the sur-
faces of the antigen-binding pockets of HLA-DR and HLA-DP
molecules.
A few reports have described 4-digit genotyping of all of three
major loci (HLA-DR, -DQ, and -DP) simultaneously in a single
cohort; thus, we assessed these loci to clarify the associations with
the HBV vaccine response. The alleles detected in the present study
were similar to those in previous vaccine studies in several other
populations. HLA-DRB1⁄01:01 and HLA-DRB1⁄08:03 were found to
be significantly more frequent in responders in Chinese, Caucasian,
and Belgian cohorts [9,29,30] and in the Korean population [7],
respectively. The identification of HLA-DQB1⁄05:01 in the present
study was concordant with reports from Chinese and Belgian pop-
ulations [9,30]. The association between HLA-DPB1⁄05:01 and a
poor response to HBV vaccination has been reported in a Tai-
wanese cohort [8], and HLA-DPB1⁄04:01 and HLA-DPB1⁄04:02 have
been reported as protective alleles in Taiwanese and Belgian pop-
ulations [8,30]. In contrast, although HLA-DRB1⁄07 has been
reported as a risk allele in many populations [7,30,31], the allele
frequency of HLA-DRB1⁄07 (⁄07:01) in the present study was only
0.26% (Supplementary Table 1); therefore, it was difficult to assess
the association.
Class II HLA proteins bind and present antigenic epitopes to
CD4-positive helper T cells and subsequently initiate the immune
A. Sakai et al. / Vaccine 35 (2017) 703–710 709response. In the present study, the protective alleles were detected
at all three loci, suggesting that multiple class II HLA proteins con-
tribute to the presentation of HBsAg epitopes. However, the iden-
tification of causal variants is difficult because of the strong LD
among alleles in HLA region.
We next examined the amino acid polymorphisms in exon 2 of
each locus, which encodes the antigen-binding sites. Our results
demonstrated the presence of independently associated amino
acid positions, all of which are located in the antigen-binding pock-
ets of HLA-DR and HLA-DP proteins. The importance of the amino
acid variations in class II HLA antigen-binding pockets, typically
pockets 1, 4, 6, and 9, has been reported in various infectious and
autoimmune diseases [27,32–34].
To the best of our knowledge, this is the first report examining
the association between amino acid residues in HLA-DRb1 and the
HBV vaccine response. The small aliphatic residue Leu26 of HLA-
DRb1 was commonly carried in the protective alleles, such as
HLA-DRB1⁄01:01 and ⁄12:01, whereas the risk direction alleles,
i.e., HLA-DRB1⁄09:01, ⁄04:06, and ⁄14:06, had large aromatic amino
acids, such as phenylalanine (Phe) or tyrosine (Tyr), at this position
(Table 3). Only the protective association of HLA-DRB1⁄08:03 was
not explainable by Leu26. Structural studies revealed that position
26 of HLA-DRb1 was located at the surface of the pocket 4, and all
of the three amino acid variants at this position had hydrophobic
properties. Thus, we expect that differences in the hydrophobic
interactions or shapes of the pockets, mediated by the amino acid
variants at position 26 (Leu, Phe, and Tyr), may affect the antigen-
binding affinity [33]. Furthermore, a cellular experimental study
has shown that changing only residue 26 of HLA-DRb1 has pro-
found effects on T-cell recognition [35]. When the complex of the
antigenic epitopes and class II HLA molecules is recognized by
the T-cell receptor, variants at position 26 may induce significant
functional differences in the T lymphocyte-mediated immune
response.
In addition to HLA-DRb1, conditional logistic regression analysis
showed that positions 84–87 of HLA-DPb1 were also indepen-
dently associated with the HBV vaccine response. A previous study
in Taiwanese individuals demonstrated an association between the
response to the booster HBV vaccination and amino acid variants at
these positions [8]. In the present study, our structural analysis
demonstrated that the amino acid residue at position 84 consti-
tuted the bottom of the pocket 1 of HLA-DP protein. Additionally,
assessment of the surface electrostatic properties clarified the
obvious major difference between GGPM and DEAV, suggesting
that these variants are key determinants of the affinity for HBsAg
epitopes, which regulates the vaccine response. The importance
of the amino acids at positions 84–87 and pocket 1 of HLA-DP
molecule as the functional unit for the antigen-binding specificity
was also described in other antigens [26,36].
In summary, our results indicated that the independently asso-
ciated amino acid variants caused significant changes in the struc-
tural and electrostatic properties of class II HLA antigen-binding
pockets, representing the major host genetic determinants of the
HBV vaccine response. These amino acid changes contribute to
the different anti-HBs production, likely by influencing the binding
affinity of HBsAg epitopes and the presentation to CD4-positive T
lymphocytes. Further studies on class II HLA proteins with regard
to HBsAg at the molecular level, particularly functional analysis
and trans-ethnic examinations, will facilitate the development of
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